Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial - Wikidata - awgldk - TriplyDB

Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial

Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial

http://www.wikidata.org/entity/Q35168763

about

Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization Precision medicine for cancer with next-generation functional diagnostics Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies Molecular Technologies in the Clinical Diagnostic Laboratory Mutant HRAS as novel target for MEK and mTOR inhibitors Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls The possibility of clinical sequencing in the management of cancer Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes Live cumulative network meta-analysis: protocol for second-line treatments in advanced non-small-cell lung cancer with wild-type or unknown status for epidermal growth factor receptor Patient-derived xenograft platform of OSCC: a renewable human bio-bank for preclinical cancer research and a new co-clinical model for treatment optimization.Genomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma.Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review.High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice.Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.Chemotherapy-induced neutropenia during adjuvant treatment for cervical cancer patients: development and validation of a prediction model.Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib.Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer Precision oncology based on omics data: The NCT Heidelberg experience.RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies."Cancer 2015": A Prospective, Population-Based Cancer Cohort-Phase 1: Feasibility of Genomics-Guided Precision Medicine in the Clinic The VA Point-of-Care Precision Oncology Program: Balancing Access with Rapid Learning in Molecular Cancer Medicine.Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.Expansion platform type II: testing a treatment strategy.Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma Institutional implementation of clinical tumor profiling on an unselected cancer population.An 8-gene signature for prediction of prognosis and chemoresponse in non-small cell lung cancer.Targeting Signaling Transduction Pathways in Bladder Cancer.Liquid biopsies in lung cancer-time to implement research technologies in routine care?Emerging targeted therapies in non-small cell lung cancer.Selumetinib for the treatment of non-small cell lung cancer.Radiogenomics and radiotherapy response modeling.Interpretation of lung cancer study outcomes.Selumetinib in the treatment of non-small-cell lung cancer.Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.Clinical Trials in the Genomic Era.

P2860

Q26765060-51CACFCD-FE1C-4903-9536-E064295B3873 Q26780232-19FB8F32-73DD-4B9F-B31E-53CB6401FFE3 Q26852049-988092A4-C7A3-4B00-9654-51A5FBB91A32 Q26996463-0D64FF95-85E6-4F8F-86E8-09D13EBEA3BC Q27853238-C5885AF8-43E9-4EA7-941F-BEE9CD1956F0 Q27853282-BFC0A6A7-CDC6-4EA5-A5FE-77C23CA98610 Q28066709-B8D292A1-C042-4EF2-AED7-20FC3CBE1CFD Q28072144-D6B9B54A-CA95-4FF5-AE27-762AE83FB0E8 Q28083446-F4B47A30-AAFB-472C-B60D-84D18BA85B18 Q28087370-B3B6BC33-B35E-46F1-87F5-5BB714628281 Q28597805-163125EA-1563-4B38-8DD3-18AF45430B6B Q33457995-30C8EBE6-F06E-4FDD-9292-1227E4E8BC4B Q33888432-FA595643-B95D-4762-84F7-AE275D570538 Q33888813-3CB6AB76-3E41-45B4-BBC9-51DB16ED3BE5 Q34529131-7668C40A-548F-42C6-A1CF-B412B592A925 Q35793906-97D65100-C12D-4F78-AE5D-F8D3875C86CF Q35845580-6B91CE96-794C-4A16-9D4E-2EED4E5A24A2 Q36035933-28A33002-C7F3-4890-B125-D5C761037C49 Q36046284-F2CB7BC8-3922-4B2D-9C29-2FAD5FC55A9F Q36117718-29ECF8D6-418A-4B13-9989-E99AD2E3BB03 Q36260477-71E86788-D749-4D13-963F-80AA00E1B0AC Q36396606-BF439762-EC85-4664-A571-18F0EC5BB215 Q36398735-9289FBF0-B130-42DA-B046-76CB5018759E Q36416071-39E5C42C-7AC9-4FA4-A444-A208954216AA Q36635960-1FE20129-96C8-4B23-9B53-2BA30D553FE0 Q36716682-25240592-1546-475D-8C4A-FEC34BE2A1EC Q37181647-D3474EA8-74CB-4082-BCAD-03873C8B3B78 Q37190448-96063992-BDBF-44B3-AA14-30D280BC567C Q37301779-31FEB61D-91C2-4161-A0E8-171850F1B8F4 Q37417570-0C6C4CCB-7469-4D8C-B57F-C531B6479999 Q37699284-B878E751-4CD6-47E4-8129-2FE23E4C816F Q38608540-E62C28F0-3580-4D8D-8E08-69EBCF75A4BC Q38649535-A1376941-EF3C-4310-8C3D-B19CA94F3799 Q38653045-6767C15E-0F19-4EB2-ADBA-6757D13B7F4C Q38663069-C3DCB70A-118F-47B2-BC32-406C67BAE23C Q38665620-340529B6-50F7-41E7-8AA8-2E1F8656833A Q38682736-5490CEA1-5A60-4566-8983-8A33E29F9703 Q38836927-4A1AA57A-3A98-4CE2-856F-06F23CD0EEBA Q38838757-045E5487-9F9C-490D-B075-59D578DDE05D Q38905607-DF8EF9F2-EF3D-4D68-BA7C-69D0B88C79FA

P2860

Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial

http://www.wikidata.org/entity/Q35168763

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Molecular profiling and target ...... istology phase II basket trial

@ast

Molecular profiling and target ...... istology phase II basket trial

@en

type

label

Molecular profiling and target ...... istology phase II basket trial

@ast

Molecular profiling and target ...... istology phase II basket trial

@en

prefLabel

Molecular profiling and target ...... istology phase II basket trial

@ast

Molecular profiling and target ...... istology phase II basket trial

@en

P1433

Q35168763-B35960A8-81D0-4409-B486-9372001566FB

P1476

Q35168763-111E1347-9BC7-4706-BEA5-FABBD469F75A

P2093

Q35168763-054AA38C-BC21-4F83-8D9F-3B4898FE7796

Q35168763-180A8F19-3CC9-4B38-B9E4-3D0C91AE150F

Q35168763-19235068-5479-45CD-9DBB-6F11B7764087

Q35168763-21857DD3-3AE0-4FB7-BF49-B8AF7F2A6BC7

Q35168763-279E22AE-D51B-454E-82A7-956DE0DB32CF

Q35168763-356DD73C-5869-43C2-A902-FE0D64330E98

Q35168763-3C3C09BD-E38F-47C3-93A6-68E99EC74135

Q35168763-3E41C4AE-EB38-4AC4-9D03-40F1892A9415

Q35168763-42329D18-9ACB-4539-95D2-AF9C6DE5605D

Q35168763-47688478-99AB-48D0-8CAE-F5750683C488

P2860

Q35168763-003709F0-3804-43FF-9687-74A914CCA615

Q35168763-019C520F-FC32-49E7-AEEA-A5DFC80FE8CE

Q35168763-04400AC7-27ED-42A8-AAF0-D59EB9CDBF9C

Q35168763-09F8EEA4-0843-4DF0-9A5C-3FC989434338

Q35168763-188765B6-3EA1-4CD7-BC1D-C9736233192C

Q35168763-1D4522E0-6624-4212-82D2-16DF79C45ECB

Q35168763-258C6773-56F5-4418-97DE-BAEE561B044A

Q35168763-2FA07A3E-84BA-462E-A5EC-3DF18DF57E99

Q35168763-4C7AB7E8-060E-4DC1-ACB3-8461C8F95417

Q35168763-4F93916A-0C00-4C06-9870-14D7BA86F3F0

P304

Q35168763-91BD93D9-47C6-49AA-8984-13C9B2D154F7

P31

Q35168763-832A7E2C-AFAB-40E0-A09F-C805FBBFA085

P356

Q35168763-445131E7-9B7A-43FF-BC4A-C9B5AC1A4784

P407

Q35168763-8529D049-90E7-4807-BD30-48CD54A551EB

P433

Q35168763-9E474FFF-BE28-46C1-A15E-C6105E6025FB

P478

Q35168763-884F2F5D-5F0F-4B21-9268-BEC4302A8FA9

P50

Q35168763-34A26276-134A-4CB9-8BE7-CC04C3621C29

Q35168763-C7CA0D1B-2F9C-4B11-B093-A47A258BD1A8

Q35168763-D2976252-5926-487E-8552-A18524BFABE8

Q35168763-DCC2C901-F26A-447C-971D-39652B947EA7

P577

Q35168763-3D2D8AF6-4F98-4468-A537-6F6490B65A21

P5875

Q35168763-F0CE0048-B6E4-4E5C-916E-936AB35C2B58

P698

Q35168763-785A4800-933F-486A-A751-BCA497EF52E1

P921

Q35168763-2C1A23C1-10FD-4EE5-B315-61C092BC8E05

Q35168763-4E06DD87-6694-4C18-A3A9-ECF6F0877195

P932

Q35168763-0B4ED2CE-2E24-4ECB-A1DD-13CA388A9C0A

P356

JCO.2014.58.2007

P1433

Journal of Clinical Oncology

P1476

Molecular profiling and target ...... istology phase II basket trial

@en

P2093

Alan Sandler

http://www.w3.org/2001/XMLSchema#string

Andrea Warrick

http://www.w3.org/2001/XMLSchema#string

Ariel Lopez-Chavez

http://www.w3.org/2001/XMLSchema#string

Arlene Berman

http://www.w3.org/2001/XMLSchema#string

Arun Rajan

http://www.w3.org/2001/XMLSchema#string

Austin Doyle

http://www.w3.org/2001/XMLSchema#string

Betsy Morrow

http://www.w3.org/2001/XMLSchema#string

Carol Beadling

http://www.w3.org/2001/XMLSchema#string

Christopher C Lau

http://www.w3.org/2001/XMLSchema#string

Christopher L Corless

http://www.w3.org/2001/XMLSchema#string

P2860

Comprehensive molecular portraits of human breast tumours

Somatic mutations affect key pathways in lung adenocarcinoma

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

ROS1 rearrangements define a unique molecular class of lung cancers.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Clinical trial designs for cytostatic agents: are new approaches needed?

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

Comprehensive genomic characterization of squamous cell lung cancers.

P304

1000-1007

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2014.58.2007

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Giaccone

Svetlana D. Pack

P577

2015-02-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272095350

http://www.w3.org/2001/XMLSchema#string

P698

25667274

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

4356709

http://www.w3.org/2001/XMLSchema#string